Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.22 - $0.56 $440 - $1,120
-2,000 Reduced 3.32%
58,330 $16,000
Q1 2022

May 02, 2022

SELL
$0.22 - $0.96 $2,421 - $10,567
-11,008 Reduced 15.43%
60,330 $30,000
Q4 2021

Jan 28, 2022

SELL
$0.88 - $1.78 $15,751 - $31,860
-17,899 Reduced 20.06%
71,338 $65,000
Q3 2021

Nov 16, 2021

SELL
$1.48 - $2.65 $54,464 - $97,520
-36,800 Reduced 29.2%
89,237 $133,000
Q2 2021

Aug 10, 2021

SELL
$2.41 - $7.11 $107,124 - $316,039
-44,450 Reduced 26.07%
126,037 $317,000
Q1 2021

May 13, 2021

BUY
$4.7 - $7.17 $12,690 - $19,359
2,700 Added 1.61%
170,487 $1.04 Million
Q4 2020

Feb 04, 2021

BUY
$2.95 - $11.04 $64,605 - $241,775
21,900 Added 15.01%
167,787 $999,000
Q3 2020

Nov 09, 2020

BUY
$9.37 - $12.06 $409,347 - $526,865
43,687 Added 42.75%
145,887 $1.58 Million
Q2 2020

Jul 31, 2020

BUY
$8.29 - $11.47 $51,397 - $71,114
6,200 Added 6.46%
102,200 $1.1 Million
Q1 2020

May 06, 2020

BUY
$6.44 - $11.32 $127,190 - $223,570
19,750 Added 25.9%
96,000 $859,000
Q4 2019

Feb 10, 2020

BUY
$5.26 - $9.6 $13,150 - $24,000
2,500 Added 3.39%
76,250 $732,000
Q3 2019

Nov 12, 2019

BUY
$5.58 - $6.3 $50,220 - $56,700
9,000 Added 13.9%
73,750 $440,000
Q2 2019

Aug 05, 2019

BUY
$4.33 - $6.54 $23,815 - $35,970
5,500 Added 9.28%
64,750 $408,000
Q1 2019

May 08, 2019

SELL
$4.75 - $6.59 $33,250 - $46,130
-7,000 Reduced 10.57%
59,250 $282,000
Q4 2018

Feb 08, 2019

BUY
$2.1 - $5.6 $6,300 - $16,800
3,000 Added 4.74%
66,250 $358,000
Q3 2018

Nov 08, 2018

BUY
$2.75 - $4.21 $5,500 - $8,420
2,000 Added 3.27%
63,250 $179,000
Q2 2018

Oct 05, 2018

SELL
$3.58 - $4.96 $3,580 - $4,960
-1,000 Reduced 1.61%
61,250 $220,000
Q1 2018

May 15, 2018

BUY
$3.64 - $5.75 $24,570 - $38,812
6,750 Added 12.16%
62,250 $281,000
Q4 2017

Feb 15, 2018

BUY
$3.53 - $5.64 $142,965 - $228,420
40,500 Added 270.0%
55,500 $201,000
Q3 2017

Nov 13, 2017

BUY
$5.08 - $6.68 $76,200 - $100,200
15,000
15,000 $83,000

About AVENUE THERAPEUTICS, INC.


  • Ticker ATXI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 4,127,720
  • Market Cap $8.13M
  • Description
  • Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was in...
More about ATXI
Track This Portfolio

Track National Asset Management, Inc. Portfolio

Follow National Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on National Asset Management, Inc. with notifications on news.